A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy by Jones, Takako I. & Jones, Peter L.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2018-02-07 
A cre-inducible DUX4 transgenic mouse model for investigating 
facioscapulohumeral muscular dystrophy 
Takako I. Jones 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Cell Biology Commons, Congenital, Hereditary, and Neonatal Diseases and Abnormalities 
Commons, Developmental Biology Commons, Developmental Neuroscience Commons, Genetic 
Phenomena Commons, Musculoskeletal Diseases Commons, and the Nervous System Diseases 
Commons 
Repository Citation 
Jones TI, Jones PL. (2018). A cre-inducible DUX4 transgenic mouse model for investigating 
facioscapulohumeral muscular dystrophy. Open Access Articles. https://doi.org/10.1371/
journal.pone.0192657. Retrieved from https://escholarship.umassmed.edu/oapubs/3356 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
RESEARCH ARTICLE
A cre-inducible DUX4 transgenic mouse model
for investigating facioscapulohumeral
muscular dystrophy
Takako Jones1,2*, Peter L. Jones1,2*
1 Department of Pharmacology, Center for Molecular Medicine, University of Nevada, Reno School of
Medicine, Reno, Nevada, United States of America, 2 Department of Cell and Developmental Biology,
University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
* takakojones@med.unr.edu (TIJ); peterjones@med.unr.edu (PLJ)
Abstract
The Double homeobox 4 (DUX4) gene is an important regulator of early human develop-
ment and its aberrant expression is causal for facioscapulohumeral muscular dystrophy
(FSHD). The DUX4-full length (DUX4-fl) mRNA splice isoform encodes a transcriptional
activator; however, DUX4 and its unique DNA binding preferences are specific to old-world
primates. Regardless, the somatic cytotoxicity caused by DUX4 expression is conserved
when expressed in cells and animals ranging from fly to mouse. Thus, viable animal models
based on DUX4-fl expression have been difficult to generate due in large part to overt devel-
opmental toxicity of low DUX4-fl expression from leaky transgenes. We have overcome this
obstacle and here we report the generation and initial characterization of a line of conditional
floxed DUX4-fl transgenic mice, FLExDUX4, that is viable and fertile. In the absence of cre,
these mice express a very low level of DUX4-fl mRNA from the transgene, resulting in mild
phenotypes. However, when crossed with appropriate cre-driver lines of mice, the double
transgenic offspring readily express DUX4-fl mRNA, protein, and target genes with the spa-
tiotemporal pattern of nuclear cre expression dictated by the chosen system. When cre is
expressed from the ACTA1 skeletal muscle-specific promoter, the double transgenic ani-
mals exhibit a developmental myopathy. When crossed with tamoxifen-inducible cre lines,
DUX4-mediated pathology can be induced in adult animals. Thus, the appearance and pro-
gression of pathology can be controlled to provide readily screenable phenotypes useful for
assessing therapeutic approaches targeting DUX4-fl mRNA and protein. Overall, the FLEx-
DUX4 line of mice is quite versatile and will allow new investigations into mechanisms of
DUX4-mediated pathophysiology as well as much-needed pre-clinical testing of DUX4-tar-
geted FSHD interventions in vivo.
Introduction
Facioscapulohumeral muscular dystrophy (FSHD) is caused by epigenetic dysregulation of the
4q35 D4Z4 macrosatellite repeat, which leads to aberrant myogenic expression of the Double
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homeobox 4 (DUX4) gene. DUX4 encodes a paired homeobox domain transcriptional activator
and regulator of cleavage-stage genes and therefore is not typically expressed in healthy
somatic cells [1–10]. In FSHD, however, DUX4 misexpression in differentiated skeletal muscle
ultimately initiates numerous potentially detrimental events including the induction of apo-
ptosis [11–14], and activation of the inflammatory immune response [15, 16].
While several DUX4 alternative mRNA isoforms are generated by alternate 5’splice site
usage in the first exon, only the DUX4-full length (DUX4-fl) mRNA is pathogenic [4, 5, 17].
DUX4-fl expression is highly regulated and apparently restricted to testis and cleavage-stage
embryos where the DUX4-mediated transcriptional program is key for human zygotic genome
activation, supporting a normal function for DUX4-FL in germ cells and during early human
development [1, 3, 5, 18, 19]. However, individuals meeting the genetic, epigenetic, and clinical
criteria for FSHD express stable DUX4-fl mRNA and DUX4-FL target genes in their skeletal
muscles, initiating a detrimental cascade of events which culminate in muscle pathology and
disease [4–6, 9, 10, 20, 21]. Somatic expression of DUX4-flmRNA per se is not necessarily path-
ogenic since rare expression can be detected in some cultures of healthy myogenic cells and
muscle biopsies, albeit at levels significantly lower than those found in similar tissues from
FSHD-affected subjects, suggesting that the levels and/or timing of somatic DUX4 expression
dictate disease [6–8]. Thus, aberrantly increased DUX4 expression is the primary mediator of
FSHD pathophysiology, the DUX4-fl mRNA and protein are prime FSHD therapeutic targets,
and animal models for FSHD should be based on expression of DUX4.
FSHD is an autosomal dominant, gain-of-function disease and thus should be amenable to
modeling in mice by overexpression of DUX4-flmRNA. However, animal models of FSHD
have suffered from serious issues with respect to pathogenic expression levels, tissue distribu-
tion, and cellular toxicity [12, 22–26]. Early attempts to model the disease in mice using viral
over-expression produced massive pathology and physiological effects not characteristic of
FSHD [13], resulting in conclusions based on artifacts [27]. Conversely, the D4Z4-2.5 trans-
genic mouse model, in which a pathogenic FSHD1-sized D4Z4 repeat array consisting of 2.5
D4Z4 repeat units [28, 29], including the distal DUX4 polyadenylation site rendering the distal
repeat unit capable of producing the stable DUX4-flmRNA [4], suffered from too little DUX4
expression in muscle and failed to show an FSHD-like phenotype [23]. When levels of the
FSHD modifier gene, Smchd1, were decreased, the levels of DUX4-flwere increased and the
phenotypes were exacerbated, however, the model still failed to recapitulate FSHD-like muscle
pathology [26]. Interestingly, a tetracycline regulated transgenic knock-in DUX4 mouse model
that suffered from severe pathology and early lethality was recently rescued by inserting an
inefficient DUX4 mRNA polyadenylation signal to decrease leaky DUX4-fl transgene expres-
sion allowing for animals to survive and develop FSHD-like phenotypes in muscles [24, 30].
Together, these cases highlight both the importance and difficulty of mimicking the patho-
genic mechanisms of FSHD in mouse models [31].
In FSHD, the DUX4 gene is typically expressed in only a small fraction (<1%) of myogenic
cells, ultimately leading to debilitating muscle pathology over time [5, 6, 32]. This may account,
in part, for the generally late onset of clinical symptoms in FSHD patients. In addition,
DUX4-fl is expressed in sporadic bursts in differentiated FSHD muscle cells, an event that is
epigenetically suppressed in healthy and asymptomatic subjects [7, 14, 33]. However, DUX4-fl
expression in affected FSHD muscle, even when bursting, is still extremely rare, highly vari-
able, and difficult to detect [5, 6, 14]. Thus, based on our current understanding of the FSHD
pathogenic mechanism, adult-onset, mosaic transgene expression in skeletal muscle is neces-
sary for modeling an FSHD-relevant DUX4 expression profile and is key to achieving FSHD-
like pathophysiology. Yet nothing is known about potential developmental or extra-muscular
contributions of DUX4-fl expression to FSHD. Ideally, a mouse model for investigating this
A transgenic mouse model for FSHD research
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disease should incorporate flexibility in dictating DUX4-fl expression, and thus allow some of
these critical questions to be addressed.
Here we report the generation and initial characterization of a conditional DUX4-fl trans-
genic mouse model, termed FLExDUX4. Similar to the situation in FSHD, DUX4-fl is expressed
at extremely low levels in adolescents and adult FLExDUX4mice. Mating with cre-expressing
lines of mice leads to induction of DUX4-fl in the spatiotemporal manner of the cre driver,
thereby providing a highly flexible model for investigating the effects of DUX4-fl expression.
When crossed with a skeletal muscle-specific, tamoxifen inducible cre-expressing mouse strain,
skeletal muscles of the double transgenic offspring can be induced to produce mosaic expression
patterns of DUX4-fl expression in a fraction of skeletal myonuclei, similar to the spontaneous
mosaic bursting of DUX4-fl expression found in FSHD skeletal myocytes [14], ultimately result-
ing in an FSHD-like myopathy. Thus, FLExDUX4mice are a useful model for both developmen-
tal and disease-relevant studies on DUX4-fl, and provide a suitable model for FSHD therapeutic
interventions targeting DUX4-fl mRNA, protein, and certain downstream pathways.
Materials and methods
Ethics statement
All animal procedures were approved by the local IACUC committees at the University of
Massachusetts Medical School and the University of Nevada, Reno. The work performed at
the University of Nevada, Reno was approved under protocol #0701. The work performed at
the University of Massachusetts Medical School was approved under protocols #A-2447-13
and #A-2535-16. Anesthesia was performed using isoflurane inhalation. Euthanasia was per-
formed using isoflurane inhalation followed by exsanguination.
Transgenic mouse generation and crosses
Transgenic mice were generated by genOway SA (France) using the FLEx directional switch
system to bypass the embryonic lethality from leaky embryonic DUX4 transgene expression
[34, 35]. The DUX4 genomic sequence (S1 Sequence), containing all three exons and both
introns, was synthesized in vitro with silent mutations made into the two known 5’ splicing
donor sites for the DUX4-s isoforms. This sequence was cloned into the proprietary genOway
Rosa26 targeting vector, and completely sequenced. Murine C57BL/6 ES cells were transfected
and clones were selected and screened for homologous recombination into the Rosa26 locus,
first by PCR, then confirmed by Southern blotting. Properly targeted ES cells were injected
into blastocysts and implanted to generate male chimeras. The chimeras were mated to
C57BL/6 females to confirm germline transmission. Chimeras were mated with the genOway
proprietary ubiquitous Flp recombinase expressing mice for in vivo removal of the Neomycin
selection cassette. The F1 hemizygous FLExDUX4mice devoid of the Neomycin resistance
gene were delivered to the Jones lab.
C57BL/6 mice and the following Cre driver lines were purchased from Jackson Labs (Bangor,
Maine): ACTA1-MCM refers to B6.Cg-Tg(ACTA1-cre/Esr1)2Kesr/J (JAX 025750), Sox2-cre
refers to B6.Cg-Tg(Sox2-cre)1Amc/J (JAX 008454), ACTA1-cre refers to B6.Cg-Tg(ACTA1-cre)
79Jme/J (JAX 006149), UBC-cre/ERT2 refers to B6.Cg-Tg(UBC-cre/ERT2)1Ejb/J (JAX 008085),
and Pax7-cre/ERT2 refers to B6.Cg-Pax7<tm1(cre/ERT2)Gaka>/J (JAX 017763).
Transgenic mouse genotyping
Genomic DNA was isolated from 2mm tail snips from <10-day-old mice. PCRs were per-
formed with ~100ng genomic DNA, 1X GoTaq Buffer, 200μM dNTPs, 0.5U GoTaq DNA
A transgenic mouse model for FSHD research
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polymerase (Promega), 600nM primer TJ76F (5’-CAATACCTTTCTGGGAGTTCTCTGCTGC),
400nM primer TJ77R (5’- CTCGTGTAGACAGAGCCTAGACAATTTGTTG), 200nM primer
TJ78R (5’- TGCAGGACAACGCCCACACACC).Reactions were incubated at 94˚C for 3min,
then cycled 30 times (94˚C for 20sec, 62˚C for 20sec, 72˚C for 35sec), followed by a final 2min
extension at 72˚C. Reactions were separated on a 1.5% agarose gel and visualized by ethidium
bromide staining. Homozygous pups produce a 409bp product, hemizygous pups produce
409bp and 175bp products, and wild type pups produce a 175bp product.
Transgene recombination
Genomic DNA was isolated from the organic phase of TRIzol RNA tissue extractions as per
manufacturer’s protocol. Two PCRs were performed on genomic DNA (50ng/reaction) using
0.1μl GoTaq (Promega) in 1X GoTaq buffer, 200μM dNTPs, 400nM primer TJ76F (5’-CAA
TACCTTTCTGGGAGTTCTCTGCTGC), and either 400nM reverse primer TJ77R (5’-CTCGTG
TAGACAGAGCCTAGACAATTTGTTG) for detecting the non-recombined transgene (406bp
product) or 400nM reverse primer 14A2-Rev (5’-AGGCTCGCAGGGCCTCGCTT) for detect-
ing the recombined transgene (440bp product). Reactions were incubated at 94˚C for 3min,
then cycled 32 times (94˚C for 20sec, 62˚C for 20sec, 72˚C for 35sec), followed by a final 2min
extension at 72˚C. Reactions were electrophoresed in separate wells of the same 1.5% agarose
gel and visualized by ethidium bromide staining. Band intensities were quantified and the
recombination rate was calculated as % recombination = TJ76F;14A2-Rev band / (TJ76F;
TJ77R band + 76F;14A2-Rev band) x 100.
Tamoxifen (TMX) administration
For intraperitoneal (IP) injections of TMX, tamoxifen free base (Sigma #T5648) was dissolved
in 100% ethanol (200mg/ml) at 55˚C and added to warm sterile corn oil (ThermoFisher
S25271) to make a 20mg/ml stock. Stock TMX aliquots were warmed to 37˚C, briefly, and
diluted further with warm corn oil 10-fold just prior to use. Twelve-week-old mice were
weighed and injected IP on two consecutive days with the appropriate volume (100μl for a 20g
mouse) of TMX for a final concentration of 10mg/kg. Alternatively, when specifically indi-
cated, TMX-laced chow (400mg/kg tamoxifen citrate) purchased from Envigo (TD.130860)
was provided ad libitum for 5 days providing an average daily dose of ~40mg/kg for 20-25g
body weight assuming a 3-4g daily food intake.
DNA methylation analysis
Genomic DNA was isolated from dissected muscle samples using TRIzol (ThermoFisher), as
per manufacturer’s instructions, bisulfite converted, and analyzed using the bisulfite sequenc-
ing 4qA (BSSA) protocol, as described [7, 36].
Gene expression analysis by RT-PCR
Total RNA was extracted from dissected mouse muscles homogenized in 10 volumes TRIzol
(ThermoFisher) using the TissueLyser LT (Qiagen), as per manufacturer’s instructions, fol-
lowed by clean-up using the RNeasy mini kit (Qiagen) to remove all remaining genomic DNA.
Qualitative expression of the 1.4kb DUX4-flRT-PCR product was performed as described [4].
Control reactions skipping the first-strand synthesis step were performed to ensure purity of
the RNA samples and assuring the results were not from contaminating genomic DNA. Quan-
titative DUX4-flmRNA expression was analyzed using nested qRT-PCR, as described [37].
Expression of DUX4 target genes was analyzed by qPCR using 5-50ng cDNA, generated with
A transgenic mouse model for FSHD research
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iScript Supermix (Bio-Rad) per manufacturer’s instructions. Expression of DUX4-flwas nor-
malized to 18S rRNA or RpL37 RNA as indicated, expression of target genes was normalized
to RpL37 RNA. Oligonucleotide primer sequences for DUX4-fl,RpL37, and 18S rRNA are as
previously reported [33]. Oligonucleotide primer sequences for Trim36, Wfdc3, and Cxcr4 are
as previously reported [23].
Alcian blue staining
The E16.5 embryos were obtained from crossing male ACTA1-cre/+ with female FLExDUX4/
+, and the extraembryonic membrane of each embryo was collected and used for genotyping.
Alcian blue staining of the fetal E16.5 cartilaginous skeleton was performed as described [38].
Briefly, embryos were dissected at stage 16.5 d.p.c. in PBS and the extraembryonic membrane
was removed and used for genotyping. Embryos were fixed in Bouin’s fixative for 2h, washed
in ammonium hydroxide:ethanol solution for 24h with 6 changes of solution and equilibrated
in 5% acetic acid twice for 1hr each. Embryos were soaked in alcian blue stain for 2h, washed
twice in 5% acetic acid for 1h each, then cleared in methanol (2X for 1h each) and then finally
in BABB (benzyl alcohol:benzyl benzoate) solution. The stained embryos were imaged using
the Leica MZ7.5 and Zeiss Axiocam.
Histology
Freshly dissected muscles were kept moist, coated with O.C.T. compound, frozen in
liquid nitrogen-cooled isopentane and stored at -80˚C until sectioning. The 10–12μm cryosec-
tions were mounted on slides, air-dried for 30 min before staining or storage. Sections were
fixed with cold acetone for 5 min for Hematoxylin and Eosin staining or picrosirius red
staining.
Picrosirius red staining
Staining was performed as described [39]. Cryosections (12μm) cut mid belly of the Tibialis
anterior muscle or heart were mounted and fixed in 4% paraformaldehyde/PBS for 10 min,
rinsed with dH2O, and then dehydrated with a series of 30 sec ethanol washes (70%, 95%,
100%) and air dried. Sections were stained for 1 hr in fresh picrosirius red solution (0.1%
direct red 80, 1.3% saturated picric acid), washed twice with 0.5% acetic acid and three times
with dH2O. Stained sections were dehydrated with a series of ethanol washes (70% for 30 sec,
95% for 30 sec, and 100% for 1 min), cleared with xylene for 5 min, and mounted with Cytoseal
60. A series of micrographs from each muscle section were captured using a 10X objective on a
Leica DM2000 and reconstituted to form an entire muscle cross-section. A custom script was
written in MATLAB (Mathworks) to determine the number of pixels stained red and the total
number of pixels stained. Muscles from 3 mice, 5 sections per muscle, for each treatment were
analyzed.
DUX4 Immunohistochemistry
Tissue sections were fixed with 4% paraformaldehyde/PBS on ice for 20 min, permeabilized
with 0.25% TritonX-100/PBS for 10 min, then incubated with blocking solution (5% normal
goat serum (NGS), 2% BSA, 0.01% TritonX-100/PBS) for 30 min. Sections were incubated
with DUX4 E5-5 antibody (1:200, abcam) at 4˚C overnight, then subsequently incubated with
Alexa 594 Goat anti-rabbit IgG (1:500, ThermoFisher) at room temperature for 40 min.
Stained sections were mounted in ProLong Gold with DAPI for nuclear staining.
A transgenic mouse model for FSHD research
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Four-limb hanging test
A 6x6-inch wire mesh made of 2-mm thick stainless steel wire was hand-held ~35-cm above a
layer of soft bedding material. Mice were allowed to grasp the middle of the mesh in an upright
position and acclimated. The mesh was slowly rotated until inverted, the timer was started,
and time until the mouse fell to the bedding was recorded. Each mouse was given three trials
per session and the longest hang time was recorded.
Results
Generation and Characterization of the FLExDUX4mouse line
Our goal was to generate a viable and fertile transgenic mouse model containing an intact
human DUX4 transgene that, upon controlled induction, produces mosaic expression and a
myopathic phenotype [4, 10, 18]. While the DUX family of transcription factors is functionally
conserved in mammals, the intact human DUX4 gene is specific to old-world primates and not
found in mice [2, 3, 19, 40]. Therefore, investigating the potential pathogenic effects of
DUX4-fl expression in mice requires the human DUX4 gene to be incorporated into the
mouse genome. To accomplish this, we synthesized a DUX4 transgene that retained the intact
human DUX4-fl gene structure, including the 5’untranslated region (UTR), all three exons and
both introns, the endogenous PAS, and the distal auxiliary elements that enhance DUX4
mRNA cleavage and polyadenylation events (Fig 1A, S1 Sequence) [1, 5, 17, 41, 42]. Impor-
tantly, many of these elements are prime targets for sequence-based therapies [43, 44]. We
incorporated four silent mutations in the 5’ splice acceptor sites for the two most prominent
DUX4 alternative mRNA isoforms found in myogenic cells. These transcripts encode the non-
pathogenic DUX4-short (DUX4-S) isoforms, which have a dominant negative effect on
DUX4-FL; thus, it was important to prevent their expression from our DUX4 transgene [5].
We also chose not to add any epitope tag to the DUX4-flmRNA sequence that might interfere
with splicing, downstream functions of the protein, or therapeutic targeting. Following trans-
fection of our DUX4 expression construct into murine C2C12 cells, we confirmed its function-
ality by RT-PCR, and the lack of detectable expression of DUX4-s mRNA (S1 Fig). Finally,
because DUX4-FL is highly cytotoxic during vertebrate development, resulting in past failures
or extreme phenotypes of transgenic mice [12, 22–24], the transgene was engineered using the
FLEx directional switch system (Fig 1B) to bypass the embryonic lethality from leaky embry-
onic DUX4 transgene expression [34, 35]. The FLExDUX4 transgene targeted the Rosa26 locus
such that it would recombine in the antisense orientation. The transgene was flanked by heter-
ologous loxP sites that recombine unidirectionally upon exposure to Cre recombinase, result-
ing in DUX4-flmRNA expression under transcriptional control of the Rosa26 promoter. This
design resulted in the successful generation of the hemizygous FLExDUX4 line of mice in a
C57BL/6 background, formally referred to as B6(Cg)-Gt(ROSA)26Sortm1.1(DUX4)/Plj/J, which
we have made available to the FSHD research community prior to this initial publication
(Jackson Laboratories catalog #028710). The available hemizygous line has been crossed with
the background mouse strain (C57BL/6) at least 5 times. DNA methylation analysis of the
transgene shows no changes in the pattern of transgene hypomethylation across all five genera-
tions (S2 Fig).
Initial observations of the FLExDUX4/+hemizygous mice indicated that they are viable, fer-
tile, live a normal life span (~2yrs), and appear generally healthy with the exception of a very
mild alopecia (Fig 2A–2D) and slightly reduced size (Fig 2F). Hemizygous males were similar
in weight to non-transgenic C57BL/6 littermate controls through the first 8 weeks after birth,
at which point the FLExDUX4/+males displayed slower growth, resulting in mice ~14% (~5g)
A transgenic mouse model for FSHD research
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smaller by 20 weeks of age. Female hemizygous mice were comparable in size to controls
through 12 weeks before their weight gain slowed, resulting in ~11% (~3g) smaller adult
females. Surprisingly, despite their more normal size and weight, alopecia becomes more
severe in adult female hemizygous mice than in their male counterparts (S3 Fig).
FLExDUX4/FLExDUX4homozygous mice were similarly viable and fertile, but showed a
much more severe alopecia compared with hemizygous and non-transgenic littermates, that
periodically appears between 3–8 weeks of age and then remains in older animals (Fig 2E and
S4 Fig). Most FLExDUX4 homozygous mice lived a normal life span, although some developed
rectal prolapse after 6 months of age and had to be euthanized. In addition, the homozygous
FLExDUX4mice had generally soft stools, and males developed an inflamed preputial gland
Fig 1. Transgene map and transgenic model generation. (A) The synthesized FLExDUX4 transgene, which maintains the 3 exon and 2 intron structure of the
human DUX4 gene, but lacks the DUX4 promoter, was inserted in the antisense orientation to the Rosa26 promoter. The transgene is flanked by heterologous lox
sites (loxP and lox511) that unidirectionally recombine in the presence of cre recombinase to invert the FLExDUX4 transgene to the sense orientation. DUX4-fl
mRNA is then transcribed from the Rosa26 promoter, processed, and terminated by the DUX4 exon3 PAS. (B) The genome targeting scheme for knocking in to the
Rosa26 locus utilized the FLEx system methodology. PGK-NeoR: phosphoglycerate kinase I promoter regulating the neomycin resistance gene. DTA: Diphtheria
toxin A gene used for counter selection.
https://doi.org/10.1371/journal.pone.0192657.g001
A transgenic mouse model for FSHD research
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(S4 Fig), suggesting potential inflammation in the gastrointestinal tract. Homozygous FLEx-
DUX4 male mice were smaller from birth compared with hemizygous and control mice, with
weight gain peaking at 9 weeks of age (~24g vs ~26g FLExDUX4/+ and ~30g WT) and plateau-
ing between 21-23g for the next 8 weeks, resulting in adults ~43% smaller than WT and 33%
smaller than hemizygous littermates (Fig 2F). Interestingly, unlike the males, female homozy-
gous FLExDUX4mice were similar in size to their hemizygous littermates through the first 20
weeks. All hemi- and homozygous mice appeared active and healthy, eating and drinking nor-
mally, similar to their control non-transgenic littermates, indicating that these changes are not
due to reduced caloric intake. The reason for the gender-specific effect on size is not known.
Together, these transgene-linked phenotypes with apparent transgene dosage effects led us to
suspect that the DUX4 transgene was being expressed at very low levels in the absence of cre-
mediated recombination, despite the gene being in the antisense orientation to the Rosa26
promoter.
To assess potential leaky expression of the DUX4 transgene, we performed sense strand-
specific quantitative reverse transcriptase PCR (qRT-PCR) for polyadenylated DUX4-flmRNA
Fig 2. The FLExDUX4 lines of mice. (A-D) Hemizygous ()FLExDUX4/+ mice are healthy, active, and fertile with a very mild alopecia that is readily
distinguishable from wildtype littermates starting at two weeks of age. (E) Homozygous FLExDUX4/FLExDUX4 mice are also healthy, active, and fertile but show
more prominent alopecia than hemizygous mice. F) These transgenic mice are initially similar in size and weight as their control non-transgenic siblings; however,
the hemizygous and homozygous are smaller as adults. The graph shows average weights for n = 5+ animals for each genotype measured each week for 20 weeks.
https://doi.org/10.1371/journal.pone.0192657.g002
A transgenic mouse model for FSHD research
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using RNA extracted from several tissues of FLExDUX4 hemi- and homozygous mice. Sense
DUX4-flmRNA was detected in skeletal muscle, liver, and skin of all mice (Fig 3A). Homozy-
gous mice, on average, showed higher DUX4-fl expression as a group in all tissues except skin
(Fig 3A), but there was mouse-to-mouse and tissue variation, and the dosage effect was not
absolute or significant between groups for any tissue, despite the more severe phenotypes (S4
Fig). Regardless, the overall DUX4-flmRNA levels detected were still very low, comparable to
those found in differentiated human FSHD myocytes (17Abic MT [6]) (Fig 3A). To assess the
scope of RNA transcript isoforms generated from the DUX4 transgene, qualitative RT-PCR
was performed using PCR primers spanning DUX4 exons 1–3 (Fig 3B), which amplify all
known DUX4 mRNA isoforms [5]. The predominant DUX4 transcript found in gastrocnemius
and tibialis anterior muscles was the predicted 1.4 kb product for DUX4-fl that retains intron
1, with a minor 1.2 kb product in which intron 1 was spliced out, as is the case in FSHD muscle
cells [5, 6, 45]. DNA sequencing confirmed that the 1.4 kb product is derived from the trans-
gene, contains the conserved splicing site changes, and is expected to encode the full open
reading frame for the pathogenic DUX4-flmRNA (S2 Sequence). Thus, skeletal muscle prefer-
entially generates the pathogenic DUX4-fl transcript, however, strikingly, both liver and skin
predominantly expressed many shorter RNAs distinct from the previously described DUX4-s
0.35 kb and 0.45 kb isoforms [5, 6], and little to none of the 1.4 kb DUX4-fl transcript (Fig 3B).
The nature of these aberrant transcripts is not clear, however, since the first strand cDNA syn-
thesis was performed with an oligo-dT primer, the negative controls resulted in no amplified
products (Fig 3B), and similarly the non-transgenic controls showed no products of any size,
all of these isoforms most likely represent polyadenylated isoforms or truncations of DUX4
transgene transcripts. DNA sequence analysis of these short products confirmed they are in
fact derived from the transgene suggesting that FLExDUX4mice express novel short DUX4
transgene transcripts in non-muscle tissues (Fig 3B). Although our approach for the efficient
expression of the DUX4-fl isoform was successful in skeletal muscle, there may be tissue-spe-
cific RNA processing of the DUX4 transgene in non-muscle tissues, which utilize variable
5’splicing donor sites and likely affects the specificity of our DUX4-flqRT-PCR assay. It should
be noted that the DUX4 qRT-PCR assay was designed and validated as specific for the DUX4-fl
mRNA in human muscle tissue and myogenic cells, not in skin or liver, since DUX4-fl is not
known to be expressed in these tissues [7, 46]. Thus, one should interpret results with caution
when using this assay alone as a measure for DUX4-flmRNA levels in non-myogenic tissues of
this mouse model.
To determine if this unexpected transgene expression was due to aberrant recombination,
genomic PCRs for the sense and antisense transgene were performed and no indication of any
genomic recombination was found (S5 Fig), thus confirming that the mRNAs are produced
from antisense transcription at the Rosa26 locus. We conclude that a sense polyadenylated
DUX4-flmRNA is being produced in skeletal muscle from the inverted transgene (Fig 1A) by
antisense transcription at the Rosa26 locus. Thus, in the absence of induction, FLExDUX4
hemi- and homozygous mice have a very low level of DUX4-flmRNA in their skeletal muscles
throughout their lifetime, yet exhibit no overt muscle phenotype. This low chronic DUX4-fl
expression without any induction may represent a useful model for testing therapies targeting
DUX4-flmRNA.
Since hemi- and homozygous FLExDUX4mice express low levels of DUX4-flmRNA in
skeletal muscles, we analyzed their muscles for DUX4-FL-mediated expression profiles and
signs of histopathology. As anticipated, since there was no transgene recombination,
DUX4-FL immunostaining of FLExDUX4/+ skeletal muscles did not reveal DUX4-FL positive
myonuclei (S6 Fig), indicating that the DUX4-flmRNA expression seen in the muscles of these
mice is likely due to very low-level expression from many or all myonuclei. DUX4-FL protein
A transgenic mouse model for FSHD research
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functions as a transcriptional activator in human and mice [23, 47]; to assess if functional levels
of DUX4-FL protein were being made, we analyzed expression of WAP four-disulfide core
domain 3 (Wfdc3), a well-documented direct murine target of overexpressed DUX4-FL pro-
tein [18, 23, 27], in gastrocnemius muscle (S7 Fig). Interestingly, Wfdc3 mRNA levels were not
significantly induced in either the hemi- or homozygous FLExDUX4muscle tissue (S7 Fig),
indicating that either no protein was being made or, more likely, that protein levels in the indi-
vidual myonuclei were too low to affect downstream gene transcription. Histological evalua-
tion of skeletal muscles similarly failed to reveal any increase in centralized nuclei, immune
cell infiltration, or fibrosis between hemi- and homozygous FLExDUX4mice and C57BL/6
Fig 3. Analysis of DUX4-flmRNA expression in FLExDUX4 hemizygous and homozygous mice reveals tissue-specific transgene splicing. (A) qRT-PCR analysis of
polyadenylated DUX4 mRNA from gastrocnemius, tibialis anterior, liver, and skin isolated from hemizygous and homozygous single transgenic FLExDUX4 mice.
Results of three individual mice for each genotype are reported, normalized to 18S rRNA. Significance was calculated using Welch’s t-test and the Mann-Whitney
unpaired t test; n.s. = not significant (p>0.05) using either test. (B) Qualitative RT-PCR spanning exons 1–3 for DUX4-fl shows that skeletal muscles predominantly
express the pathogenic 1.4kb and 1.2 kb DUX4-flmRNAs; liver and skin predominantly express aberrant short RNAs produced from the DUX4 transgene. Upper panels,
RT-PCR utilizing oligo-dT primed first strand synthesis. Lower panels, PCR without first-strand synthesis shows no genomic DNA contamination.
https://doi.org/10.1371/journal.pone.0192657.g003
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controls (Fig 4 and S8 Fig). Together, this data supports a model of FLExDUX4mice produc-
ing very low levels of leaky DUX4-flmRNA expression in all muscle cells, however, the expres-
sion levels are too little on a per cell basis to activate or at least detect induction of downstream
DUX4 target genes. This is in contrast to the situation in FSHD, where a small number of myo-
nuclei burst with high and ultimately pathogenic levels of DUX4-fl mRNA and protein expres-
sion, leading to downstream target gene activation [5, 14, 48]. This model can be readily scaled
and may be useful for assessing therapeutic approaches targeting DUX4-flmRNA in vivo.
Developmental induction of DUX4-fl expression is lethal.
While FLExDUX4 hemi- and homozygous mice express very low levels of DUX4-fl and display
mild phenotypes in fur, digestive tract, and muscle fiber type, they show no signs of a skeletal
myopathy and are generally healthy. In order to generate a model suitable for investigating
DUX4-induced myopathy, it was necessary to induce DUX4-fl expression levels using cre-
mediated recombination. As designed, cre expression in the tissues of double transgenic mice
would lead to inversion of the transgene to the sense orientation such that DUX4-flmRNA
expression would be mediated by the ubiquitous and fairly strong Rosa26 promoter [49] (Fig
1A). To assess the functionality of the floxed transgene design and ensure that cre-mediated
recombination leads to increased expression of DUX4-flmRNA, we initially crossed the FLEx-
DUX4 mice with two developmentally regulated cre expression lines of mice (Table 1). Cross-
ing with a Sox2-cre mouse [50], in which cre is expressed from the Sox2 (SRY-box containing
2) promoter in the mouse epiblast, resulted in decreased litter sizes and no double transgenic
Fig 4. FLExDUX4mice display no overt myopathy despite low-level DUX4-fl expression. Skeletal muscles were analyzed for histopathology using hematoxylin and
eosin (H&E) staining at 8, 12, 15, and 23 weeks (shown). Representative tibialis anterior sections are shown for (A) control C57BL/6, (B) FLExDUX4/+, and (C)
FLExDUX4/FLExDUX4 female mice. Scale bar = 100μm.
https://doi.org/10.1371/journal.pone.0192657.g004
Table 1. Results of FLExDUX4 crosses to cre expressing lines of mice.
Cre line Phenotype of double transgenic FLExDUX4;cre offspring
Sox2-cre [50] Embryonic lethal
ACTA1-cre [51] Stillborn E19; skeletal abnormalities
UBC-creERT2 [52] Viable; may develop severe ataxia and severe neurological phenotypes requiring
euthanasia after 5 weeks in absence of TMX
Pax7-creERT2 [53] Viable and apparently healthy in absence of TMX
ACTA1-MerCreMer
[54]
Viable, very mild muscle phenotype in absence of TMX; TMX-inducible myopathic
phenotype
https://doi.org/10.1371/journal.pone.0192657.t001
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mice after multiple matings, supporting previous work that DUX4-fl expression during early
vertebrate development is lethal [12].
To circumvent the developmental lethality of early ubiquitous DUX4-fl expression, FLEx-
DUX4 mice were crossed with ACTA1-cre mice [51], which express cre in striated muscles
from the human Skeletal α-actin (ACTA1) promoter, recapitulating the expression profile
from the endogenous murine Acta1 promoter. Male FLExDUX4/+mice crossed with female
ACTA1-cre mice and, conversely, female FLExDUX4/+mice crossed with male ACTA1-cre
mice both produced litters of normal size and typical Mendelian inheritance patterns (Fig 5).
However, all double transgenic pups (n = 7) were stillborn and smaller after developing nearly
to full term (E19.5) compared with single transgenic or WT pups (n = 9) that were uniformly
viable and healthy. RT-PCR analysis of mRNA expression confirmed that pathogenic DUX4-fl
mRNA was expressed in all pups containing the FLExDUX4 transgene, and at higher levels in
the limbs of FLExDUX4;ACTA1-cre double transgenic stillborn animals compared with their
FLExDUX4/+ sibling controls (Fig 5D). Thus, while mouse development can withstand the
very low level of leaky DUX4-fl expression found in the FLExDUX4 hemi- and homozygous
mice, increased expression levels in striated muscle during development are lethal.
Although FSHD is typically adult-onset, there is an early-onset, very severe infantile form
of the disease (IFSHD) that is poorly understood [55, 56], and early, potentially developmental
events preceding clinical presentation of FSHD are not known. One hypothesis is that bursts
of DUX4-fl expression occur earlier in IFSHD and thus start the detrimental cascade of patho-
physiology sooner than in the classical adult FSHD1. An alternative and not mutually exclusive
hypothesis is that all forms of FSHD have a developmental origin, establishing a course for
FSHD pathology well before clinical symptoms appear. DUX4-flmRNA has been detected in
genetically FSHD1 human embryonic tissues [57], supporting both hypotheses and suggesting
that its developmental increase in expression may be detrimental and a contributing factor to
increased IFSHD severity. Since the Acta1/ACTA1 promoter is active in the myotomal region
of somites as early as 9.5 days post-coitum (d.p.c) [51], we took advantage of this developmen-
tal DUX4-fl expression model, and analyzed embryos for DUX4-fl dependent musculoskeletal
defects (Fig 6). The 16.5 d.p.c. embryos were isolated from crosses of male ACTA1-cre/+ mice
with female FLExDUX4/+mice and analyzed with alcian blue staining to reveal the embryonic
cartilaginous skeleton [38, 58]. Interestingly, all ACTA1-cre;FLExDUX4 embryos (n = 12) had
overall smaller bodies compared with single transgenic siblings (Fig 6A compared with Fig
6E), aberrantly developed spinal columns (Fig 6B compared with Fig 6F), and underdeveloped
rib cages (Fig 6C and 6D compared with Fig 6G and 6H). None of these phenotypes were
found in any sibling controls (n = 36). Thus, although these specific developmental phenotypes
do not directly translate to known FSHD or IFSHD clinical phenotypes, they clearly demon-
strate that small increases in DUX4-fl expression levels in striated muscle during development
can have dramatic and deleterious effects.
Inducible crosses generate phenotypic DUX4-fl-expressing mice
Although the FLExDUX4mice are viable and relatively healthy despite the presence of low lev-
els of DUX4-fl during development, the fully penetrant stillborn phenotype of the ACTA1-cre;
FLExDUX4 double transgenic animals indicated that an adult mouse model would require
postnatal induction of DUX4-fl expression. We therefore crossed FLExDUX4mice with induc-
ible cre expressing mouse lines (Table 1). We chose three mouse lines for the crosses, each
serving different purposes: induced ubiquitous expression (UBC-cre/ERT2 line [52]), induced
limb and craniofacial skeletal muscle expression (ACTA1-MerCreMer line [54]), and induced
muscle satellite cell expression (Pax7-cre/ERT2 line [53]). Each line expresses a cre protein
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fused to estrogen receptors for strong cytoplasmic retention, and mutated such that it translo-
cates to the nucleus only in the presence of tamoxifen (TMX), and not estrogen [59]. All three
crosses with FLExDUX4mice successfully produced litters of normal size with Mendelian
inheritance, and numerous viable double transgenic offspring that survived into adulthood.
Fig 5. Increased expression of DUX4-fl in embryonic muscle is lethal by stage E19. In order to boost DUX4-fl
expression levels in skeletal muscle, the FLExDUX4/+ mice were crossed with ACTA1-cre mice. Litters were of normal
size (7–10 pups) with both (A) live and (B) stillborn pups. (C) Genotyping showed live births for all three control
genotypes; however, all resulting ACTA1-cre/+; FLExDUX4/+ double transgenic animals were stillborn. D and E)
RT-PCR shows that the full-length 1.4kb DUX4-flmRNA transcript is expressed at increased levels in the forelimbs
and hindlimbs of (D) stillborn ACTA1-cre/+; FLExDUX4/+ animals compared with (E) live born FLExDUX4/+ sibling
pups. This increased expression correlates with expression of cre recombinase. Scale bar = 5mm.
https://doi.org/10.1371/journal.pone.0192657.g005
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Fig 6. Embryonic expression of DUX4-fl results in skeletal developmental abnormalities. Stage E16.5 embryos
were isolated from crosses between ACTA1-cre/+ male and FLExDUX4/+ female mice and stained with alcian blue to
visualize the mouse fetal cartilaginous skeleton. The ACTA1-cre/+; FLExDUX4/+ double transgenic embryos (E-H)
were smaller than controls (A-D), and were the only genotype (n = 12) to show skeletal deformations in the spine,
limbs, and rib cage compared with control (n = 36) littermates (FLExDUX4/+, ACTA1-cre/+, and WT). Bars = 1mm.
https://doi.org/10.1371/journal.pone.0192657.g006
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The UBC-cre/ERT2;FLExDUX4mice ubiquitously express a TMX-inducible cre from the
human ubiquitin C promoter [52], and, in the absence of TMX administration, should not
express levels of DUX4-flmRNA above those caused by antisense transcription of the inverted
FLExDUX4 transgene. Therefore, double transgenic animals were not anticipated to have any
adverse phenotypes. However, despite apparently normal embryonic development and birth-
rates, the UBC-cre/ERT2;FLExDUX4pups (stage P10) showed delayed fur growth compared
with FLExDUX4/+ siblings (Fig 7A), which further manifested as a mild alopecia by 3 weeks of
age (Fig 7B). Unlike the FLExDUX4 hemi- and homozygous mice that remained healthy, after
5 weeks of apparently normal behavior (Fig 7C), the health of UBC-cre/ERT2;FLExDUX4mice
began to rapidly deteriorate and they developed additional phenotypes that became much
more severe (Fig 7D). Animals developed severe kyphosis and tremors, becoming unsteady
and eventually ataxic (S1 Movie). Between 5–12 weeks of age, the mice (n = 5/6) had lost their
righting reflex and began having spontaneous seizures characterized by periods (> 30sec) of
wild and uncontrolled running (S2 Movie), and required euthanasia.
These severe phenotypes beyond those seen in the FLExDUX4 hemi- and homozygous
mice suggested increased levels of DUX4-fl expression in the double transgenic animals. Anal-
ysis of genomic DNA isolated from tissues of UBC-cre/ERT2;FLExDUX4mice confirmed low
levels of cre-dependent transgene recombination specifically in the brain, but not in liver or
muscle, and were absent in the FLExDUX4/+ lines (S9 Fig), indicating a low level of functional
nuclear cre in the brains of double transgenic mice in the absence of TMX. This leaky trans-
gene recombination in the brain, but not the muscle, likely explains the severe neurological
phenotype without an obvious muscle phenotype.
To assess the phenotypic DUX4-fl expression levels, we performed qRT-PCR analysis. How-
ever, the DUX4-flmRNA levels detected in brain tissue from UBC-cre/ERT2;FLExDUX4dou-
ble transgenic animals were surprisingly similar to the DUX4-fl expression found in the brains
of non-recombined FLExDUX4/+mice (Fig 8A). In fact, there were no significant differences
in DUX4-flmRNA expression levels assayed by qRT-PCR between FLExDUX4/+ and UBC-
cre/ERT2;FLExDUX4mice for any of the tissues analyzed. Previous analysis of the FLExDUX4
single transgenic mice showed that non-myogenic tissues can produce variable short DUX4
transcripts that can affect the qRT-PCR assay, and the results may not reflect the expression
level of the pathogenic DUX4-FL protein (Fig 3). To determine the levels of functional
DUX4-FL protein in these tissues, expression of Wfdc3, a direct target of DUX4-FL protein
with minimal expression in FLExDUX4/+mice, was analyzed and showed a markedly distinct
expression pattern (Fig 8B). Despite similar DUX4-flqRT-PCR profiles between mouse strains,
Wfdc3 expression was induced >250-fold in the brains of UBC-cre/ERT2;FLExDUX4mice
compared with FLExDUX4/+mice, but only mildly, yet significantly, induced in liver or mus-
cle tissues, indicating that only the double transgenic brain had high levels of functional
DUX4-FL protein. To further address the discrepancy between DUX4 mRNA expression and
DUX4-FL target gene expression in the brain, we again performed a DUX4 RT-PCR to quali-
tatively analyze the mRNA isoforms generated from the DUX4 transgene in these tissues from
both mouse models (Fig 8C). As before (Fig 3), gastrocnemius muscle from the FLExDUX4/+
and UBC-cre/ERT2;FLExDUX4mice only produced the pathogenic DUX4-flmRNA isoform,
containing intron 1, and did not generate any DUX4-s or other alternative short mRNAs from
the transgene. In contrast, brains of FLExDUX4/+mice and, to a lesser degree, the UBC-cre/
ERT2;FLExDUX4mice expressed a combination of DUX4-flmRNA and multiple short unique
transcripts that, upon DNA sequencing (Fig 8C, ), were confirmed to be novel short DUX4
variants. Thus, alternative splicing in non-muscle tissue again contributed to a high noise for
the DUX4-flqRT-PCR analysis in the brain. Thus, the extreme behavioral and physical pheno-
types of the UBC-cre/ERT2;FLExDUX4double transgenic animals can likely be explained by
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brain-specific leakiness of cre, leading to brain-specific transgene recombination and, ulti-
mately increased levels of DUX4-flmRNA and functional DUX4-FL protein in the brain.
Upon observation of the internal organs, the subiliac lymph nodes (central drainage) and
popliteal lymph nodes (hind leg drainage) [60] were strikingly swollen in the double transgenic
mice compared with C57BL/6 and FLExDUX4 controls (S10 Fig). After weighing, both types
of lymph nodes were found to be significantly enlarged in the DUX4-fl expressing FLExDUX4/
+ (4.0 mg SD = 1.641 and 1.7 mg SD = 0.427, respectively) and UBC-creERT2;FLExDUX4 (12.5
mg SD = 8.031 and 4.4 SD = 2.935, respectively) mice compared with control mice (2.5 mg
SD = 0.601 and 0.9 mg SD = 0.326, respectively) (S10 Fig). Enlarged lymph nodes can be indic-
ative of acute inflammation, and several lines of evidence suggest inflammatory immune pro-
cesses may be involved in mediating FSHD pathophysiology [9, 15, 16, 61, 62], supporting that
an inflammatory immune response was stimulated by low-level DUX4-fl expression in these
mice. Overall, we conclude that UBC-cre/ERT2;FLExDUX4 animals, with or without TMX
Fig 7. Leaky, ubiquitous DUX4-fl expression causes a severe adult phenotype. FLExDUX4/+ mice were crossed with the UBC-creERT2 line, which
expresses a tamoxifen-inducible cre recombinase from the ubiquitous UBC promoter. (A) Double transgenic pups (age P10) were normal-sized, but
exhibited delayed hair growth. At (B) 3 weeks of age, and (C) 6 weeks of age, double transgenic pups were still normal-sized, but had noticeably more
alopecia than FLExDUX4/+ littermates. (D) By 12 weeks, most double transgenic mice had developed severe alopecia, kyphosis, ataxia, and neurological
abnormalities (S1–S3 Movies) and required euthanasia (n = 5/6; 3 male and 2 female). One male remained relatively unaffected for 16 months.
https://doi.org/10.1371/journal.pone.0192657.g007
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Fig 8. Tissue-specific DUX4-fl alternative mRNA isoforms are generated from the FLExDUX4 transgene. Three severely phenotypic 12-week-old UBC-
creERT2;FLExDUX4 (dTG) mice and three sibling FLExDUX4/+ mice were analyzed by qRT-PCR for expression of (A) DUX4-fl and (B) Wfdc3, a direct
DUX4-FL target gene, in liver, brain, and gastrocnemius muscle. The results of the three individual mice for each condition are summarized in the graphs on the
right (U = UBC-creERT2/+; F = FLExDUX4/+; dT = dTG). (C) RT-PCR analysis of FLExDUX4/+ and FLExDUX4;UBC-creERT2 mice for DUX4 mRNA isoforms
shows tissue-specific splicing and variation in expression levels. Multiple novel short DUX4mRNAs (confirmed by sequencing) are detected in the brain and
liver, but not gastrocnemius. Significance was calculated using Welch’s t-test; n.s. = not significant (p>0.05),  = p<0.05,  = p<0.005.
https://doi.org/10.1371/journal.pone.0192657.g008
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induction, express elevated levels of DUX4-FL and may be useful for evaluating certain sys-
temic effects of DUX4-fl expression for preclinical testing of molecules targeting DUX4-fl
mRNA or protein. However, due to severe neurological effects, this model did not recapitulate
an FSHD-like phenotype, and the progressive severity of the phenotype with age requires uti-
lizing young mice and administering euthanasia by 10–12 weeks of age.
Generation of an adult FSHD-like phenotype using the FLExDUX4model
Our current understanding of FSHD is that the aberrantly increased DUX4-fl expression is
generally restricted to skeletal muscles [33]. However, unlike other muscle diseases, in which
all of the myocytes of an affected individual share the same functional deficit [63], it is esti-
mated that <1% of FSHD myonuclei express the pathogenic DUX4-flmRNA at any particular
time [5, 6], and that sporadic bursts of DUX4-fl expression from an increased number of myo-
nuclei may lead to pathology [14]. Affected muscle has mosaic expression, and DUX4-fl
expressing cells are in the minority. To best recapitulate this situation in our mouse model, we
crossed FLExDUX4mice with the ACTA1-MerCreMer (ACTA1-MCM) line [54], which
expresses TMX-inducible cre in skeletal and craniofacial muscles, but not in cardiac muscle.
Presumably, the resulting ACTA1-MCM;FLExDUX4 mice would express low levels of leaky
DUX4-fl, similar to an unaffected FSHD patient, and, upon limited TMX administration,
would recombine the transgene in a fraction of myonuclei, dependent upon the amount of
TMX, to produce a mosaic DUX4-fl expression pattern in the skeletal muscles. This would
result in high levels of DUX4-fl expression from each recombined myonucleus, thus generating
a DUX4-mediated FSHD-like myopathy.
Crossing ACTA1-MCM males with FLExDUX4 females produced large litters (8–10 pups)
of viable healthy double transgenic offspring at normal Mendelian ratios. Typically, research-
ers aim for a 100% recombination rate for the transgene and use up to 75mg/kg TMX in 5 suc-
cessive intraperitoneal (IP) injections [64] to achieve this goal. However, we are interested in a
much lower recombination rate to produce mosaic expression of the DUX4 transgene and
avoid lethality. To obtain our desired phenotype, we chose two methods: 1) feeding a TMX-
laced chow ad libitum for 5 days for a predicted administration of 40mg/kg/day, and 2) direct
administration of TMX using a dosage of 20mg/kg in corn oil delivered by IP injection on two
successive days. All TMX-treated ACTA1-MCM;FLExDUX4 mice and controls were moni-
tored daily for activity and overall health. Both groups of TMX-treated ACTA1-MCM;FLEx-
DUX4 mice rapidly displayed phenotypes consistent with a progressive myopathy (S11 Fig,
S3–S10 Movies). The mice fed TMX chow lost weight and became ataxic within 8 days of
TMX exposure (S3 Movie); however, the mice did not appear to like eating the chow and food
intake was lower than with untreated food. Thus, analyzing the effects of TMX induction of
DUX4-flwas compounded by low and variable food intake and resulting weight loss, which
translated to a variable and uncontrolled dosage. We conclude that TMX-laced chow is not an
appropriate route of administration for this mouse model. In contrast, there was no such vari-
able with the mice administered TMX via IP injections. In addition, concerns about the poten-
tial effects of TMX on muscle are mitigated using this IP method since the dose is low and
exposure is very short due to TMX clearance [65]. By seven days post-injection, all double
transgenic mice showed a noticeable decline in appearance, activity (S4–S6 Movies), and
strength (S7–S10 Movies) and by nine days post-injection, they required euthanasia. By con-
trast, TMX-injected FLExDUX4/+ and ACTA1-MCM/+, as well as non-injected
ACTA1-MCM;FLExDUX4 controls, showed no adverse effects. Qualitative movement (com-
pare movies of control animal, S4 and S5 Movies with movie of affected animal, S6 Movie) and
strength measurements by a four-limb hanging test (compare movies of control animals, S7
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and S8 Movies with movies of affected animals, S9 and S10 Movies) revealed clear declines spe-
cific to the TMX-injected ACTA1-MCM;FLExDUX4 animals (e.g. 2 min maximum assay hang-
ing times for all controls and<2 sec for all TMX-injected ACTA1-MCM;FLExDUX4 affected
animals). Thus, TMX-injected ACTA1-MCM;FLExDUX4 mice develop an expected FSHD-
like phenotype.
All mice, including age-matched controls, were sacrificed nine days post-injection (13
weeks old) and muscle samples were assayed for DUX4-fl expression and histopathology. Sur-
prisingly, despite the clear phenotypes, significant increases in the steady state levels of
DUX4-flmRNA were not detected by qRT-PCR in the phenotypic ACTA1-MCM;FLExDUX4
(+TMX) mice (Fig 9A). However, immunostaining revealed mosaic DUX4-FL protein expres-
sion in the myonuclei (Fig 10I–10L), reminiscent of the sporadic natural bursting of expres-
sion seen in FSHD myonuclei, and three downstream target genes, Wfdc3, Trim36, and Cxcr4
(Fig 9B–9D), were greatly induced by TMX in the skeletal muscles of ACTA1-MCM;FLEx-
DUX4 mice. Thus, detection of these DUX4-FL downstream targets is a more accurate method
for assessing DUX4-FL levels than direct detection of DUX4-flmRNA by qRT-PCR. In addi-
tion, skeletal muscle tissues that expressed DUX4-FL showed large infiltrates of mononuclear
cells (Figs 10I and 11L and S12 Fig) and became mildly fibrotic (Fig 12). Thus, initial analysis
of the skeletal muscles of phenotypic ACTA1-MCM;FLExDUX4 mice indicate they share three
key pathological characteristics of FSHD muscle: mosaic DUX4-FL expression that leads to
DUX4-FL target gene expression, mononuclear cell infiltration, and increased fibrosis [5, 14,
15, 21, 61, 66].
Histological analysis of the tibialis anterior, gastrocnemius, and quadriceps muscles (Fig
11) showed severe pathology in the TMX-induced double transgenic animals, including the
highly heterogeneous fiber size distribution characteristic of regeneration, mononuclear cell
infiltration, and a staining pattern indicative of necrosis and phagocytosis (Fig 11I–11L). Simi-
larly, the tibialis anterior muscles in the TMX-induced double transgenic animals showed
increased fibrosis (Fig 12A–12D), indicative of aberrant deposition of extra-cellular matrix
components during tissue healing, resulting in the loss of muscle architecture common in
many muscular dystrophies including FSHD [66–69]. These phenotypes were absent from the
muscles of the double transgenic mice without TMX (Fig 11E–11H) and ACTA1-MCM (Fig
11A–11D) control mice. Interestingly, while not a dramatic phenotype, the non-induced
ACTA1-MCM;FLExDUX4 showed patches of centralized nuclei and several small irregular
fibers, indicative of muscle damage and regeneration (Fig 11H) that are not found in muscles
from the FLExDUX4/+mice. This correlated with slightly higher levels of DUX4-flmRNA and
target gene expression than those found in skeletal muscle from single transgenic mice (Fig 9),
due to a low level of leaky nuclear MerCreMer specifically in skeletal muscle leading to very
low mosaic recombination of the transgene (S5 Fig). Thus, these non-induced double trans-
genic mice alone may be a useful model of very mild DUX4-mediated pathology.
FSHD, like many myopathies, elicits an inflammatory immune response in affected muscles
that, in turn, may contribute to muscle pathophysiology [15, 16, 61, 70, 71]. Investigation of
the mononuclear cell infiltrates observed in the ACTA1-MCM;FLExDUX4 skeletal muscle his-
tograms by immunostaining for CD11b (Itgam, Integrin subunit alpha M), a member of the
CD18 integrin family of leukocyte adhesion receptors involved in leukocyte migration [72],
and Ly6g (lymphocyte antigen 6 complex, locus (G), a marker for murine neutrophils [73, 74],
confirmed the presence of pro-inflammatory cells in the affected muscle within six days of
DUX4-fl induction (Fig 13C, 13D, 13G and 13H). These immune cell infiltrates were absent
from healthy control muscles (Fig 13A, 13B, 13E, 13F and S13 Fig). By nine days, muscles were
severely affected, with massive immune cell infiltration and loss of membrane integrity, as
indicated by loss of dystrophin localization (Fig 14 and S12 Fig). Importantly, these immune
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phenotypes are consistent with FSHD pathology as identified by MRI and histopathology;
thus, this model may be useful for characterizing the role of the immune system in FSHD.
Discussion
FSHD is a dominant genetic disease with a critical epigenetic component resulting in mis-
expression of the cytotoxic isoform of the old-world primate DUX4 gene [10]. Aberrant myo-
genic expression of DUX4-fl is considered to be the main driver of pathology in FSHD. How-
ever, due to the extreme cytotoxicity of DUX4-fl, FSHD has been very difficult to model in
mice [23, 24, 75]. Here we report the generation and characterization of a conditional DUX4-fl
transgenic mouse model, termed FLExDUX4. Crossing FLExDUX4mice with cre driver lines
of mice leads to increased DUX4-flmRNA and protein expression. Use of muscle-specific cre-
driver lines of mice results in double transgenic offspring that express DUX4-flmRNA in skel-
etal muscles and develop an FSHD-like myopathic phenotype [4]. Thus, these mice should be
Fig 9. TMX induction leads to DUX4-FL target gene expression in skeletal muscle of ACTA1-MCM;FLExDUX4 mice. Gastrocnemius muscles from 13-week-old mice
were assayed 9 days post-IP injection with TMX, as indicated, and relative mRNA expression levels for DUX4-fl and three DUX4-FL target genes were determined. Each of
the 3 individual mice per group (1, 2, 3) are shown. (A) DUX4-flmRNA expression assayed by qRT-PCR does not significantly change between groups, despite increased
protein expression (Fig 11). (B) Wfdc3 mRNA expression is upregulated in both double transgenic groups compared with FLExDUX4 alone; however, TMX treatment
significantly induces Wfdc3 expression in ACTA1-MCM;FLExDUX4 compared with the untreated control ACTA1-MCM;FLExDUX4mice. In contrast, (C) Trim36 and
(D) Cxcr4mRNA expression are relatively constant and only upregulated in response to TMX induction in ACTA1-MCM;FLExDUX4mice. Significance was calculated
using Welch’s t-test; n.s. = not significant (p>0.05),  = p<0.05,  = p<0.005.
https://doi.org/10.1371/journal.pone.0192657.g009
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of great use for investigating pathogenic mechanisms and testing therapeutic approaches for
FSHD.
Key features of the FLExDUX4mouse model include the following: 1) the DUX4 transgene
maintains the 3 exon, 2 intron gene structure, including the DUX4-fl 5’ UTR, endogenous
PAS, and other important mRNA and RNA processing therapeutic targets, 2) the DUX4-fl
mRNA expressed in skeletal muscle is spliced and polyadenylated as in FSHD patients, 3)
hemizygous and homozygous FLExDUX4 single transgenic mice are healthy, fertile, and have
normal life spans, 4) FLExDUX4 single transgenic mice express a very low level of DUX4 RNA
in all tissues tested, and DUX4-flmRNA in skeletal muscles, and 5) crossing with any number
of cre-driver lines will allow investigators spatiotemporal control of DUX4-fl expression during
development or in adults.
When FLExDUX4mice are crossed with cre-expressing lines of mice, severe phenotypes
can be obtained. Crossing FLExDUX4mice with ACTA1-MCM mice [54], a skeletal muscle-
specific, TMX-inducible cre-expressing strain, produces double transgenic offspring that
themselves represent a mild model of FSHD, and can be induced to develop a severe DUX4--
dependent FSHD-like myopathy with low levels of TMX injected IP into adult animals. Upon
TMX induction, ACTA1-MCM;FLExDUX4 mice exhibit decreased movement, an altered gait,
and loss of hanging ability (S3–S10 Movies), indicating an overall decline in muscle function.
Analysis of the skeletal muscles of ACTA1-MCM;FLExDUX4 (+TMX) mice identified other
important features characteristic of FSHD. In FSHD, DUX4-flmRNA is expressed in a small
Fig 10. TMX induction leads to mosaic expression of DUX4-FL protein in myonuclei of ACTA1-MCM;FLExDUX4 mice. Gastrocnemius muscles from 13-week-old
mice 6 days post-IP injection with TMX, as indicated, were assayed by immunohistochemistry for DUX4-FL protein, counterstained with wheat germ agglutinin (WGA)
to outline myofibers, and DAPI to identify myonuclei. (A-D) ACTA1-MCM, (E-H) ACTA1-MCM;FLExDUX4 no TMX, and (I-L) ACTA1-MCM;FLExDUX4+TMX.
Arrows identify DUX4-FL positive myonuclei. Scale bar = 25μm.
https://doi.org/10.1371/journal.pone.0192657.g010
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fraction of myonuclei in skeletal muscles, and in myogenic cells in culture [5]. Similarly, our
severe FSHD-like model shows mosaic DUX4-FL protein expression in myonuclei within sev-
eral days of TMX administration (Figs 10 and 14 and S12 Fig). In humans, DUX4-FL is a tran-
scriptional activator, and induction of DUX4-FL target genes is a signature of FSHD muscle
[20]. Since DUX4-fl mRNA and protein levels are typically very low in FSHD myogenic cells,
DUX4 target genes serve as sensitive surrogate markers for levels of DUX4-FL expression.
While DUX4-fl mRNA and protein levels are also very low in this model, the mRNA levels of
DUX4-responsive genes (Wfdc3, Trim36, and Cxcr4) are significantly increased following
DUX4-fl induction (Fig 9). Although the murine and human DUX4-induced transcriptomes
only partially overlap, measuring the expression of these murine DUX4 target genes will be
useful for evaluating DUX4-fl levels during therapeutic interventions in this mouse model.
FSHD muscle biopsies and MRI data indicate an inflammatory immune response in mus-
cles of many FSHD patients [15, 16, 61, 70] and histopathology shows fibro-fatty replacement
in affected FSHD muscle [66]. Inflammatory cells are able to stimulate fibrotic activity during
regeneration and promote fibrotic tissue remodeling in Duchenne muscular dystrophy [76,
77]. Similarly, in the dystrophic ACTA1-MCM;FLExDUX4 TMX-induced mice, mosaic myo-
genic expression of DUX4-fl leads to an infiltration of inflammatory mononuclear cells,
including neutrophils and macrophages (Figs 11, 13 and 14 and S12 Fig), and increased fibro-
sis (Fig 12). Thus, these FSHD-like mice may represent a useful model for investigating the
Fig 11. Induction of DUX4-fl induces a severe myopathy in skeletal muscles of ACTA1-MCM;FLExDUX4mice. H&E staining on skeletal muscle sections from
12-week-old ACTA1-MCM/+ (A-D), ACTA1-MCM;FLExDUX4 (E-H), and ACTA1-MCM;FLExDUX4+TMX mice at 9 days post-injection (I-L). The tibialis anterior (A,
E, I), gastrocnemius (B, F, J), and quadriceps (C, G, K) muscles are shown at 10X (bars = 500μm), and the tibialis anterior (D, H, L) is shown at 40X (bars = 50 μm). Low
level skeletal muscle transgene recombination in the absence of TMX leads to a proportion of centralized nuclei, indicative of regenerating myofibers, in ACTA1-MCM;
FLExDUX4muscles (H). TMX induction in ACTA1-MCM;FLExDUX4muscles leads to increased numbers of myonuclei expressing DUX4-FL, heterogeneous fiber size
distribution, and mononuclear cell infiltration (L).
https://doi.org/10.1371/journal.pone.0192657.g011
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Fig 12. Induction of DUX4-FL expression leads to fibrosis in skeletal muscles of ACTA1-MCM;FLExDUX4 mice. Picrosirius red staining on tibialis anterior (A-C) and
heart (E-G), and summarized in (D and H), shows significantly increased fibrosis in skeletal muscles after 9 days of TMX treatment but not in the hearts of ACTA1-MCM;
FLExDUX4 mice. (D and H) Combined results from muscle obtained from 3 mice per group, 5 non-consecutive cross-section sections analyzed per muscle. Significance (
p< 0.01) was calculated using Welch’s t-test; n.s. = not significant. Bars = 500μm and 100 μm (insets).
https://doi.org/10.1371/journal.pone.0192657.g012
Fig 13. Induction of DUX4-fl leads to innate immune cell infiltration in skeletal muscles of ACTA1-MCM;FLExDUX4 mice. Gastrocnemius muscle sections from (A,
E) ACTA1-MCM, (B-D and F-H) ACTA1-MCM;FLExDUX4 mice immunostained for CD11b (A-C, and E-G) or Ly6g (E and H) reveal immune cell infiltration upon
TMX induction of DUX4-fl expression. Panels (A-D) 10X magnification, Scale bar = 100μm, (E-H) 40X magnification, Scale bar = 25μm.
https://doi.org/10.1371/journal.pone.0192657.g013
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role of the immune response in DUX4-mediated pathophysiology, including fibrosis, and for
testing therapies targeting the immune system, such as anti-inflammatories.
Conclusions
This study represents the generation and initial characterization of the conditional cre-induc-
ible FLExDUX4 line of mice to provide a foundation of information for investigators to further
develop and utilize according to their individual needs. Full characterization of this model in
respect to FSHD, including a global analysis of gene expression, muscle physiology, detailed
muscle pathology, etc., is in progress and will be part of subsequent studies. However, since we
made these mice freely available to the research community through Jackson Labs prior to any
publication, and to prevent the wasting of time and resources in experimental design, it is
important to disseminate relevant data on this model in a timely manner to researchers already
using these mice or those interested in obtaining the mice prior to a full characterization. We
show conclusively that FLExDUX4mice are a highly versatile model for manipulating DUX4-fl
expression levels in vivo. These mice can be used alone as a model of very low-level DUX4-fl
mRNA expression in all myocytes without the development of adverse phenotypes, or, alterna-
tively, in combination with cre-driver lines to force higher, pathogenic levels of DUX4-fl
expression, as desired. Importantly, we characterized ACTA1-MCM;FLExDUX4 mice, with
and without TMX, as valuable new tools for FSHD research and for pre-clinical testing of
potential FSHD therapeutics targeting DUX4-fl mRNA, protein, and certain downstream
Fig 14. Induction of DUX4-fl leads to accumulation of immune cells, loss of membrane integrity, and a necrotic myopathy in
skeletal muscles of ACTA1-MCM;FLExDUX4 mice. (A-C) Tibialis anterior muscles from myopathic ACTA1-MCM;FLExDUX4mice 8
days post TMX treatment exhibit mosaic nuclear expression of DUX4-FL and (D, E) accumulation of CD11b+ cells around damaged
and dying myofibers, distinguished by a loss of dystrophin localization (arrows). Scale bars = 25μm.
https://doi.org/10.1371/journal.pone.0192657.g014
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effects. With the FLExDUX4mice already available from Jackson Labs, this initial analysis pro-
vides the platform for allowing the field to move forward with investigations of FSHD patho-
genic mechanisms, and testing the efficacy of numerous potential therapeutic approaches
targeting DUX4-fl mRNA and protein.
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